重新审视平均风险亚洲人群结直肠癌筛查的起始年龄:一项成本效果分析
该模拟研究纳入香港10万名个体,比较40、45、50岁起始采用粪便免疫化学检测(FIT)或结肠镜筛查至75岁的成本效果。FIT起始年龄50、45、40岁的增量成本效果比(ICER)分别为53262、67892、86554美元;结肠镜分别为267669、312848、372090美元。结论认为香港45岁起始FIT筛查是平衡且具成本效果的策略。
要点
- FIT起始年龄50、45、40岁的ICER分别为53262、67892、86554美元。
- 结肠镜起始年龄50、45、40岁的ICER分别为267669、312848、372090美元。
- 依从率70%、80%、90%时,45岁起始FIT获得2135、2296、2438生命年,结肠镜获得2725、2798、2855生命年。
核心结论
- 在香港,45岁起始采用FIT进行结直肠癌筛查被判定为平衡且具成本效果的策略。
- 该策略较40岁起始筛查显示成本优势,且较50岁起始筛查挽救更多生命。
研究设计与样本
- 模拟研究纳入香港100000名个体,分别于40、45、50岁起始采用FIT或结肠镜作为初筛方法,筛查至75岁。
- 基于获得生命年评估不同策略表现,采用增量成本效果比(ICER)衡量成本效果。
主要发现
- FIT起始年龄50、45、40岁的ICER分别为53262、67892、86554美元。
- 结肠镜起始年龄50、45、40岁的ICER分别为267669、312848、372090美元。
- 总体而言,FIT策略成本较低。
- 依从率70%、80%、90%时,45岁起始FIT获得的生命年分别为2135、2296、2438,45岁起始结肠镜获得的生命年分别为2725、2798、2855。
- 随依从率提高,FIT能以更低成本节省与结肠镜相近的生命年。
关键数值与推荐
- FIT起始年龄50、45、40岁的ICER分别为53262、67892、86554美元。
- 结肠镜起始年龄50、45、40岁的ICER分别为267669、312848、372090美元。
- 依从率70%、80%、90%时,45岁起始FIT获得生命年2135、2296、2438,45岁起始结肠镜获得生命年2725、2798、2855。
临床怎么用
- 原文结论认为香港45岁起始FIT筛查是平衡且具成本效果的策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: One of the most prevalent and fatal tumors, colorectal cancer (CRC), has a significant impact on the use of healthcare services. Although Hong Kong's CRC screening program has been successful, it does not prioritize preventing early-onset CRC in people under age 50 years. This study aimed to assess the cost-effectiveness of different starting ages for CRC screening among an Asian population. METHODS: We conducted a simulation study involving 100,000 individuals in Hong Kong who were screened using either the fecal immunochemical test (FIT) or colonoscopy as primary screening methods at ages 40, 45, and 50 until age 75. The performance of different strategies was evaluated based on life-years gained, and cost-effectiveness was measured using the incremental cost-effectiveness ratio (ICER). RESULTS: The ICERs for initiating FIT screening at age 50, screening starting at age 45, and screening starting at age 40 were U.S. dollars (USD) 53,262, USD 67,892, and USD 86,554, respectively. For colonoscopy, the ICERs for initiating screening at ages 50, 45, and 40 were USD 267,669, USD 312,848, and USD 372,090, respectively. Overall, the FIT strategy was found to be less costly. At 70%, 80%, and 90% compliance rates, the FIT at age 45 gained 2135, 2296, and 2438 life-years, respectively, whereas colonoscopy at age 45 gained 2725, 2798, and 2855 life-years, respectively. With increased compliance rates, the FIT could save a similar number of life-years as colonoscopy with lower cost. CONCLUSIONS: Initiating CRC screening at age 45 using the FIT in Hong Kong was determined to be a well-balanced and cost-effective strategy. This approach demonstrated a cost advantage over starting screening at age 40 and resulted in more lives saved compared with screening at age 50.
引用
- Huang J, Chan VCW, Chen M, et al. Revisiting the starting age of colorectal cancer screening for the average-risk Asian population: a cost-effectiveness analysis. Gastrointest Endosc. 2025. PMID: 40024296. doi:10.1016/j.gie.2025.02.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。